Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Roekaerts, PMHJ.
Right arrow Articles by De Lange, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roekaerts, PMHJ.
Right arrow Articles by De Lange, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, Vol 77, Issue 3 427-429, Copyright © 1996 by The Board of Management and Trustees of the British Journal of Anaesthesia

SHORT COMMUNICATIONS

Beneficial effects of dexmedetomidine on ischaemic myocardium of anaesthetized dogs

PMHJ. Roekaerts, F. W. Prinzen and S. De Lange
Department of Anaesthesiology, University Hospital of Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands; Department of Physiology and Anaesthesiology, University Hospital of Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands

We have studied the effect of dexmedetomidine during coronary artery stenosis (CAS) in dogs. Three periods of 15 min of CAS were induced at 40-min intervals in two groups of dogs (dexmedetomidine compared with placebo). Dexmedetomidine was administered before the second and third periods of CAS in doses of 1 and 3 micrograms kg-1, respectively. Dexmedetomidine decreased plasma concentrations of noradrenaline by mean 71 (SEM 9)%, heart rate by 8 (4)%, cardiac output by 30 (6)% and increased mean arterial pressure by 23 (10)%. Dexmedetomidine reduced blood flow in non-ischaemic myocardium and in the ischaemic epicardial layer by 16 (8)%, but blood flow was preserved in the ischaemic mid- myocardial and subendocardial layers. Consequently, dexmedetomidine increased the ischaemic-non-ischaemic blood flow ratio. Dexmedetomidine did not change myocardial oxygen consumption but decreased myocardial oxygen demand from 4.91 (0.33) to 3.76 (0.25) microgramsmol min-1 g-1, thereby reducing the oxygen deficiency of the ischaemic myocardium from 1.47 (0.37) to 0.29 (0.32) microgramsmol min-1 g-1.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
H. Guo, S. Takahashi, S. Cho, T. Hara, S. Tomiyasu, and K. Sumikawa
The Effects of Dexmedetomidine on Left Ventricular Function During Hypoxia and Reoxygenation in Isolated Rat Hearts
Anesth. Analg., March 1, 2005; 100(3): 629 - 635.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
H. M. Willigers, F. W. Prinzen, P. M. Roekaerts, S. de Lange, and M. E. Durieux
Dexmedetomidine Decreases Perioperative Myocardial Lactate Release in Dogs
Anesth. Analg., March 1, 2003; 96(3): 657 - 664.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.